MAP4K2 and acute myeloid leukemia: Previously, we reported that dual inhibition of activated cdc42-associated kinase 1 (ACK1) and germinal center kinase (GCK) can be a novel therapeutic strategy to overcome acute myeloid leukemia (AML) harboring NRAS mutation (25).